BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33303420)

  • 1. Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study.
    Li B; Guo J; Li T; Gu J; Zeng C; Xiao M; Zhang W; Li Q; Zhou J; Zhou X
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e198-e205. PubMed ID: 33303420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
    El-Mallawany NK; Curry CV; Allen CE
    Br J Haematol; 2022 Jan; 196(1):31-44. PubMed ID: 34169507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
    Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
    Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.
    Zhang J; Qin S; Jin Z; Chen Q; Xing L; Qiu T; Xia Y; Liang J; Zhu H; Wang L; Fan L; Xu W; Li J; Miao Y
    J Clin Immunol; 2023 Aug; 43(6):1302-1310. PubMed ID: 37093406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis-a dangerous disease.
    Jin Z; Wang Y; Wei N; Wang Z
    Ann Hematol; 2020 Jul; 99(7):1575-1581. PubMed ID: 32500223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiological findings and treatment of EBV-associated hemophagocytic lymphohistiocytosis: a case report.
    Przybylski M; Dzieciatkowski T; Zduńczyk D; Jedrzejczak WW; Luczak M
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):247-52. PubMed ID: 20383798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group.
    Kogawa K; Sato H; Asano T; Ohga S; Kudo K; Morimoto A; Ohta S; Wakiguchi H; Kanegane H; Oda M; Ishii E
    Pediatr Blood Cancer; 2014 Jul; 61(7):1257-62. PubMed ID: 24535916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis and follow-up study of Epstein-Barr virus associated-hemophagocytic lymphohistiocytosis in childhood].
    Lu G; Xie ZD; Shen KL; Wu RH; Jin YK; Yang S; Liu CY
    Zhonghua Er Ke Za Zhi; 2010 Feb; 48(2):121-6. PubMed ID: 20426937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients.
    Zhao A; Yang J; Li M; Li L; Gan X; Wang J; Li H; Shen K; Yang Y; Niu T
    Front Immunol; 2022; 13():882589. PubMed ID: 35479073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
    Chen R; Lin Q; Zhu Y; Shen Y; Xu Q; Tang H; Cui N; Jiang L; Dai X; Chen W; Li X
    Orphanet J Rare Dis; 2023 Sep; 18(1):297. PubMed ID: 37736751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis.
    Koizumi Y; Imadome KI; Ota Y; Minamiguchi H; Kodama Y; Watanabe D; Mikamo H; Uehira T; Okada S; Shirasaka T
    J Clin Immunol; 2018 May; 38(4):478-483. PubMed ID: 29687211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells.
    Fox CP; Shannon-Lowe C; Gothard P; Kishore B; Neilson J; O'Connor N; Rowe M
    Clin Infect Dis; 2010 Jul; 51(1):66-9. PubMed ID: 20504238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignancy-associated hemophagocytic lymphohistiocytosis in children: a 10-year experience of a single pediatric hematology center.
    Huang Z; Jia Y; Zuo Y; Wu J; Lu A; Zhang L
    Hematology; 2020 Dec; 25(1):389-399. PubMed ID: 33161882
    [No Abstract]   [Full Text] [Related]  

  • 14. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Blood-Based Inflammatory Biomarkers in Secondary Hemophagocytic Lymphohistiocytosis.
    Huang J; Yin G; Duan L; Tian T; Xu J; Wang J; Gao X; Cheng W; Liu L; Qiu H
    J Clin Immunol; 2020 Jul; 40(5):718-728. PubMed ID: 32495220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features and outcome analysis of 83 childhood Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with HLH-2004 protocol].
    Xiao L; Xian Y; Dai BT; Su YC; Xiao JW; Zheng QC; Zhao XD; Yu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):668-72. PubMed ID: 22339824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious consequences of Epstein-Barr virus infection: Hemophagocytic lymphohistocytosis.
    Xu L; Guo X; Guan H
    Int J Lab Hematol; 2022 Feb; 44(1):74-81. PubMed ID: 34709704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target.
    Chuang HC; Lay JD; Hsieh WC; Su IJ
    Cancer Sci; 2007 Sep; 98(9):1281-7. PubMed ID: 17627615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan.
    Wang RC; Chang ST; Hsieh YC; Huang WT; Hsu JD; Tseng CE; Wang MC; Hwang WS; Wang J; Chuang SS
    Int J Clin Exp Pathol; 2014; 7(5):2430-7. PubMed ID: 24966953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.